Do analysts rate CURX or PLRZ?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Curanex Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Polyrizon 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, CURX or PLRZ?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Curanex Pharmaceuticals N/A N/A -$4.22M -$7.80 N/A Polyrizon N/A N/A -$3.34M N/A N/A

Is CURX or PLRZ more profitable?

Polyrizon's return on equity of 0.00% beat Curanex Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Curanex Pharmaceuticals N/A -82.07% -79.65% Polyrizon N/A N/A N/A

Do analysts prefer AYTU or CURX?

Aytu BioPharma presently has a consensus target price of $14.50, suggesting a potential upside of 600.48%. Given Aytu BioPharma's stronger consensus rating and higher possible upside, research analysts plainly believe Aytu BioPharma is more favorable than Curanex Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aytu BioPharma 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Curanex Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer CURX or TXMD?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Curanex Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 TherapeuticsMD 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate CURX or QNTM?

Quantum Biopharma has a consensus price target of $8.00, suggesting a potential upside of 132.56%. Given Quantum Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe Quantum Biopharma is more favorable than Curanex Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Curanex Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Quantum Biopharma 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger valuation and earnings, CURX or QNTM?

Quantum Biopharma is trading at a lower price-to-earnings ratio than Curanex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Curanex Pharmaceuticals N/A N/A -$4.22M -$7.80 N/A Quantum Biopharma N/A N/A -$26.17M -$5.49 N/A

Is CURX or QNTM more profitable?

Curanex Pharmaceuticals' return on equity of -82.07% beat Quantum Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Curanex Pharmaceuticals N/A -82.07% -79.65% Quantum Biopharma N/A -582.23% -184.20%

Do analysts recommend BGM or CURX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BGM Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Curanex Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, BGM or CURX?

Curanex Pharmaceuticals has lower revenue, but higher earnings than BGM Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BGM Group $37.92M 0.80 -$19.94M N/A N/A Curanex Pharmaceuticals N/A N/A -$4.22M -$7.80 N/A

Is BGM or CURX more profitable?

BGM Group's return on equity of 0.00% beat Curanex Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets BGM Group N/A N/A N/A Curanex Pharmaceuticals N/A -82.07% -79.65%

Curanex Pharmaceuticals (CURX) Competitors

$4.72 -0.25 (-5.03%)

Closing price 10/2/2026 03:51 PM Eastern

Extended Trading

$5.05 +0.33 (+6.97%)

As of 10/2/2026 07:30 PM Eastern

Compare

CURX vs. PLRZ, AYTU, TXMD, QNTM, and BGM

Should you buy Curanex Pharmaceuticals stock or one of its competitors? Curanex Pharmaceuticals's main competitors and comparable companies include Polyrizon (PLRZ), Aytu BioPharma (AYTU), TherapeuticsMD (TXMD), Quantum Biopharma (QNTM), and BGM Group (BGM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Curanex Pharmaceuticals compare to Polyrizon?

Curanex Pharmaceuticals (NASDAQ:CURX) and Polyrizon (NASDAQ:PLRZ) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and valuation.

Polyrizon's return on equity of 0.00% beat Curanex Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Curanex Pharmaceuticals	N/A	-82.07%	-79.65%
Polyrizon	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Curanex Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Polyrizon	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Curanex Pharmaceuticals has a beta of -2.88, meaning that its share price is 388% less volatile than the broader market. Comparatively, Polyrizon has a beta of -1.2, meaning that its share price is 220% less volatile than the broader market.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Curanex Pharmaceuticals	N/A	N/A	-$4.22M	-$7.80	N/A
Polyrizon	N/A	N/A	-$3.34M	N/A	N/A

In the previous week, Polyrizon had 3 more articles in the media than Curanex Pharmaceuticals. MarketBeat recorded 3 mentions for Polyrizon and 0 mentions for Curanex Pharmaceuticals. Polyrizon's average media sentiment score of 0.73 beat Curanex Pharmaceuticals' score of 0.00 indicating that Polyrizon is being referred to more favorably in the news media.

Company	Overall Sentiment
Curanex Pharmaceuticals	Neutral
Polyrizon	Positive

Summary

Polyrizon beats Curanex Pharmaceuticals on 6 of the 6 factors compared between the two stocks.

How does Curanex Pharmaceuticals compare to Aytu BioPharma?

Aytu BioPharma (NASDAQ:AYTU) and Curanex Pharmaceuticals (NASDAQ:CURX) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, institutional ownership, media sentiment, risk, dividends, analyst recommendations, profitability and earnings.

Curanex Pharmaceuticals has lower revenue, but higher earnings than Aytu BioPharma. Aytu BioPharma is trading at a lower price-to-earnings ratio than Curanex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aytu BioPharma	$57.57M	0.39	-$14.25M	-$1.66	N/A
Curanex Pharmaceuticals	N/A	N/A	-$4.22M	-$7.80	N/A

Curanex Pharmaceuticals has a net margin of 0.00% compared to Aytu BioPharma's net margin of -24.76%. Aytu BioPharma's return on equity of -56.54% beat Curanex Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aytu BioPharma	-24.76%	-56.54%	-13.14%
Curanex Pharmaceuticals	N/A	-82.07%	-79.65%

Aytu BioPharma presently has a consensus target price of $14.50, suggesting a potential upside of 600.48%. Given Aytu BioPharma's stronger consensus rating and higher possible upside, research analysts plainly believe Aytu BioPharma is more favorable than Curanex Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aytu BioPharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Curanex Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

33.5% of Aytu BioPharma shares are held by institutional investors. 4.9% of Aytu BioPharma shares are held by company insiders. Comparatively, 39.7% of Curanex Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Aytu BioPharma has a beta of 0.17, meaning that its stock price is 83% less volatile than the broader market. Comparatively, Curanex Pharmaceuticals has a beta of -2.88, meaning that its stock price is 388% less volatile than the broader market.

In the previous week, Aytu BioPharma had 9 more articles in the media than Curanex Pharmaceuticals. MarketBeat recorded 9 mentions for Aytu BioPharma and 0 mentions for Curanex Pharmaceuticals. Curanex Pharmaceuticals' average media sentiment score of 0.00 beat Aytu BioPharma's score of -0.15 indicating that Curanex Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Aytu BioPharma	Neutral
Curanex Pharmaceuticals	Neutral

Summary

Aytu BioPharma beats Curanex Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Curanex Pharmaceuticals compare to TherapeuticsMD?

Curanex Pharmaceuticals (NASDAQ:CURX) and TherapeuticsMD (NASDAQ:TXMD) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

30.7% of TherapeuticsMD shares are held by institutional investors. 39.7% of Curanex Pharmaceuticals shares are held by company insiders. Comparatively, 1.7% of TherapeuticsMD shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

TherapeuticsMD has higher revenue and earnings than Curanex Pharmaceuticals. Curanex Pharmaceuticals is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Curanex Pharmaceuticals	N/A	N/A	-$4.22M	-$7.80	N/A
TherapeuticsMD	$3.02M	7.85	-$570K	$0.02	102.50

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Curanex Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Curanex Pharmaceuticals has a net margin of 0.00% compared to TherapeuticsMD's net margin of -6.64%. TherapeuticsMD's return on equity of -1.09% beat Curanex Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Curanex Pharmaceuticals	N/A	-82.07%	-79.65%
TherapeuticsMD	-6.64%	-1.09%	-0.78%

Curanex Pharmaceuticals has a beta of -2.88, indicating that its share price is 388% less volatile than the broader market. Comparatively, TherapeuticsMD has a beta of 0.65, indicating that its share price is 35% less volatile than the broader market.

In the previous week, Curanex Pharmaceuticals' average media sentiment score of 0.00 equaled TherapeuticsMD'saverage media sentiment score.

Company	Overall Sentiment
Curanex Pharmaceuticals	Neutral
TherapeuticsMD	Neutral

Summary

TherapeuticsMD beats Curanex Pharmaceuticals on 8 of the 10 factors compared between the two stocks.

How does Curanex Pharmaceuticals compare to Quantum Biopharma?

Curanex Pharmaceuticals (NASDAQ:CURX) and Quantum Biopharma (NASDAQ:QNTM) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Curanex Pharmaceuticals' return on equity of -82.07% beat Quantum Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Curanex Pharmaceuticals	N/A	-82.07%	-79.65%
Quantum Biopharma	N/A	-582.23%	-184.20%

Quantum Biopharma is trading at a lower price-to-earnings ratio than Curanex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Curanex Pharmaceuticals	N/A	N/A	-$4.22M	-$7.80	N/A
Quantum Biopharma	N/A	N/A	-$26.17M	-$5.49	N/A

1.2% of Quantum Biopharma shares are held by institutional investors. 39.7% of Curanex Pharmaceuticals shares are held by insiders. Comparatively, 8.5% of Quantum Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Quantum Biopharma has a consensus price target of $8.00, suggesting a potential upside of 132.56%. Given Quantum Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe Quantum Biopharma is more favorable than Curanex Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Curanex Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Quantum Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Quantum Biopharma had 1 more articles in the media than Curanex Pharmaceuticals. MarketBeat recorded 1 mentions for Quantum Biopharma and 0 mentions for Curanex Pharmaceuticals. Curanex Pharmaceuticals' average media sentiment score of 0.00 equaled Quantum Biopharma'saverage media sentiment score.

Company	Overall Sentiment
Curanex Pharmaceuticals	Neutral
Quantum Biopharma	Neutral

Curanex Pharmaceuticals has a beta of -2.88, indicating that its stock price is 388% less volatile than the broader market. Comparatively, Quantum Biopharma has a beta of 0.39, indicating that its stock price is 61% less volatile than the broader market.

Summary

Quantum Biopharma beats Curanex Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

How does Curanex Pharmaceuticals compare to BGM Group?

BGM Group (NASDAQ:BGM) and Curanex Pharmaceuticals (NASDAQ:CURX) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends, media sentiment and analyst recommendations.

In the previous week, BGM Group had 6 more articles in the media than Curanex Pharmaceuticals. MarketBeat recorded 6 mentions for BGM Group and 0 mentions for Curanex Pharmaceuticals. Curanex Pharmaceuticals' average media sentiment score of 0.00 beat BGM Group's score of -0.33 indicating that Curanex Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
BGM Group	Neutral
Curanex Pharmaceuticals	Neutral

BGM Group has a beta of 1.85, suggesting that its share price is 85% more volatile than the broader market. Comparatively, Curanex Pharmaceuticals has a beta of -2.88, suggesting that its share price is 388% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BGM Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Curanex Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

BGM Group's return on equity of 0.00% beat Curanex Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BGM Group	N/A	N/A	N/A
Curanex Pharmaceuticals	N/A	-82.07%	-79.65%

Curanex Pharmaceuticals has lower revenue, but higher earnings than BGM Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BGM Group	$37.92M	0.80	-$19.94M	N/A	N/A
Curanex Pharmaceuticals	N/A	N/A	-$4.22M	-$7.80	N/A

Summary

BGM Group beats Curanex Pharmaceuticals on 5 of the 7 factors compared between the two stocks.

Get Curanex Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CURX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CURX vs. The Competition

Export

Metric	Curanex Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$7.40M	$12.28B	$7.15B	$13.28B
Dividend Yield	N/A	2.65%	2.54%	17.33%
P/E Ratio	-0.61	802.26	274.71	26.04
Price / Sales	N/A	940.01	656.46	105.13
Price / Cash	N/A	86.66	78.87	52.62
Price / Book	0.60	10.52	10.93	6.31
Net Income	-$4.22M	$2.86B	$3.51B	$362.16M
7 Day Performance	-0.11%	-1.58%	-2.00%	-1.66%
1 Month Performance	-6.53%	-5.55%	-6.19%	-4.68%
1 Year Performance	-69.74%	-2.19%	8.03%	1.57%

Curanex Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CURX Curanex Pharmaceuticals	0.386 of 5 stars	$4.72 -5.0%	N/A	-69.7%	$7.40M	N/A	N/A	6
PLRZ Polyrizon	1.1368 of 5 stars	$11.06 -0.9%	N/A	+46.9%	$26.57M	N/A	N/A	1	Earnings Report Gap Up
AYTU Aytu BioPharma	3.2915 of 5 stars	$2.33 +2.2%	$10.75 +361.4%	+8.9%	$25.00M	$57.57M	N/A	83	Analyst Revision Gap Up
TXMD TherapeuticsMD	0.5248 of 5 stars	$2.16 -0.5%	N/A	+91.2%	$24.99M	$3.02M	108.00	420
QNTM Quantum Biopharma	2.0431 of 5 stars	$3.91 +0.6%	$8.00 +104.9%	-81.4%	$24.99M	N/A	N/A	7

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CURX) was last updated on 10/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Curanex Pharmaceuticals (CURX) Competitors

CURX vs. PLRZ, AYTU, TXMD, QNTM, and BGM

How does Curanex Pharmaceuticals compare to Polyrizon?

Summary

How does Curanex Pharmaceuticals compare to Aytu BioPharma?

Summary

How does Curanex Pharmaceuticals compare to TherapeuticsMD?

Summary

How does Curanex Pharmaceuticals compare to Quantum Biopharma?

Summary

How does Curanex Pharmaceuticals compare to BGM Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CURX vs. The Competition

Curanex Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Curanex Pharmaceuticals (CURX) Competitors

CURX vs. PLRZ, AYTU, TXMD, QNTM, and BGM

How does Curanex Pharmaceuticals compare to Polyrizon?

Is CURX or PLRZ more profitable?

Do analysts rate CURX or PLRZ?

Which has more volatility & risk, CURX or PLRZ?

Which has stronger earnings and valuation, CURX or PLRZ?

Does the media favor CURX or PLRZ?

Summary

How does Curanex Pharmaceuticals compare to Aytu BioPharma?

Which has better earnings & valuation, AYTU or CURX?

Is AYTU or CURX more profitable?

Do analysts prefer AYTU or CURX?

Do institutionals and insiders hold more shares of AYTU or CURX?

Which has more volatility & risk, AYTU or CURX?

Does the media refer more to AYTU or CURX?

Summary

How does Curanex Pharmaceuticals compare to TherapeuticsMD?

Do insiders & institutionals hold more shares of CURX or TXMD?

Which has preferable earnings and valuation, CURX or TXMD?

Do analysts prefer CURX or TXMD?

Is CURX or TXMD more profitable?

Which has more risk & volatility, CURX or TXMD?

Does the media prefer CURX or TXMD?

Summary

How does Curanex Pharmaceuticals compare to Quantum Biopharma?

Is CURX or QNTM more profitable?

Which has stronger valuation and earnings, CURX or QNTM?

Do insiders and institutionals hold more shares of CURX or QNTM?

Do analysts rate CURX or QNTM?

Does the media prefer CURX or QNTM?

Which has more volatility & risk, CURX or QNTM?

Summary

How does Curanex Pharmaceuticals compare to BGM Group?

Does the media refer more to BGM or CURX?

Which has more volatility & risk, BGM or CURX?

Do analysts recommend BGM or CURX?

Is BGM or CURX more profitable?

Which has higher valuation and earnings, BGM or CURX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CURX vs. The Competition

Curanex Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools